Every 10-Q that Kairos Pharma, Ltd. (KAPA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KAPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KAPA filings page.
Kairos Pharma, Ltd. reported no revenue and a net loss of $3,042 thousand for the six months ended June 30, 2026, compared with a loss of $2,684 thousand a year earlier, reflecting higher research and development spending of $1,303 thousand and general and administrative expenses of $1,804 thousand.
Cash and cash equivalents were $2,626 thousand and total assets $4,456 thousand, while operating cash outflows were $2,048 thousand in the first half of 2026. The company raised $392 thousand in gross proceeds via an at-the-market offering during the period and another $911 thousand afterward. Management and the auditor state that recurring losses, cash burn, and limited cash raise substantial doubt about Kairos’ ability to continue as a going concern. Disclosure controls and procedures were also concluded to be not effective. Kairos remains a clinical-stage oncology biotech with multiple license and manufacturing commitments and no approved products.
Kairos Pharma, Ltd. reports Q1 2026 results with a net loss of $1,654 thousand, wider than $1,262 thousand a year earlier, and no revenue. Operating expenses rose to $1,690 thousand, driven by higher research and development and public-company costs.
Cash and cash equivalents were $3,675 thousand at March 31, 2026, down from $4,491 thousand at year-end 2025. The company raised gross proceeds of $385 thousand (net $367 thousand) via an At the Market equity program and has an Equity Line of Credit and a $75,000 thousand shelf registration available.
The filing states that recurring losses, cash used in operations of $1,036 thousand in the quarter, and limited cash raise substantial doubt about Kairos’s ability to continue as a going concern. The company is committing to additional manufacturing and development agreements for its ENV-105 program and has signed a binding term sheet to acquire CL-273 in exchange for equity and future milestones, increasing its need for external financing.
Kairos Pharma (KAPA) reported Q3 2025 results. The company recorded a net loss of $1.4 million for the quarter and $4.1 million for the nine months ended September 30, 2025, with no revenue reported. Operating expenses rose as development advanced: R&D was $608k in Q3 ($1.6 million year‑to‑date) and G&A was $827k in Q3 ($2.6 million year‑to‑date).
Liquidity improved through 2025 financings. Cash and cash equivalents were $5.6 million and shareholders’ equity was $7.7 million at September 30, 2025. Year‑to‑date financing cash inflows included $3.1 million net from January pre‑funded units and $3.6 million from the equity line of credit. The company expects current cash to fund operations for at least 12 months from the filing date. Common shares outstanding were 20,821,353 as of November 14, 2025. Subsequent events include a $1.143 million Lonza agreement tied to ENV105 Phase 3 manufacturing preparation and new RSU grants for executives and directors.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing immunotherapy and cell therapy candidates. As of June 30, 2025, the company held $3,034 in cash and cash equivalents and reported a six-month net loss of $2,684. Operating expenses for the six months were $2,722, driven by $989 of R&D (including Phase 2 ENV105 prostate and Phase 1 ENV105 lung trials and a Phase 1 for KROS201) and $1,733 of general and administrative costs. Accumulated deficit was $11,499 and shareholders' equity was $5,997.
The company raised capital in 2025 via a January PIPE (net proceeds $3,058) and draws under a $30,000 Equity Line of Credit (ELOC), selling 3,510,000 ELOC shares for aggregate net proceeds of $3,903 as of the filing and an additional 3,000,000 ELOC shares for $3,693 in July 2025. Deferred offering costs totaled $1,692. Vendor advances, net, were $1,717 with significant amortization in the period. The company states current cash is expected to fund operations for at least 12 months, but continues to depend on future financings to execute its development plan.